# BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting scheduled for Sept. 18. Nutriband emphasized that the NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. If approved, the patch could become the first and only abuse-deterrent transdermal fentanyl product globally, with peak annual sales estimated between $80 million and $200 million. AVERSA Buprenorphine, the company’s second program, is projected to reach peak annual sales of up to $130 million. Nutriband continues to grow revenue through its Pocono Pharma contract manufacturing subsidiary, which contributed to the record first half.

 To view the full press release, visit https://ibn.fm/spHiy

 About Nutriband Inc.

 We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

 The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-nutriband-inc-nasdaq-ntrb-reports-51-revenue-growth-strong-cash-position-to-advance-aversa-fentanyl/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-s-aversa-fentanyl-patch-nears-fda-review-with-51-revenue-surge/7f1b9c59f156c5c7af0d13b8ced104df) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202509/204410-nutriband-inc-reports-51-revenue-growth-and-strong-cash-position-to-advance-aversa-fentanyl-program)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202509/204409-nutriband-inc-reporta-crecimiento-de-ingresos-del-51-y-avances-en-su-tecnologia-aversatm-para-prevenir-el-abuso-de-fentanilo)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202509/204502-nutriband-inc-verzeichnet-51-umsatzwachstum-und-starkt-finanzlage-fur-aversa-fentanyl-entwicklung)

Pickup - [https://actueclair.com](https://actueclair.com/202509/204468-nutriband-inc-enregistre-une-croissance-de-51-des-revenus-et-renforce-sa-position-de-tresorerie-pour-faire-avancer-aversa-fentanyl)

Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202509/204618-faq-nutriband-inc-financial-results-and-aversa-fentanyl-development)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202509/204637-faq-nutriband-inc-s-financial-growth-and-aversa-fentanyl-development)
 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1ndjwme/nutribands_aversa_fentanyl_patch_nears_fda_review/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/10/barn1bZk.webp)